anakinra


( Last Updated : October 27, 2021)
Generic Name:
anakinra
Project Status:
Withdrawn
Therapeutic Area:
Still's disease
Manufacturer:
Swedish Orphan Biovitrum AB
Call for patient/clinician input open:
Brand Name:
Kineret
Project Line:
Reimbursement Review
Project Number:
SR0662-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open November 16, 2020
Call for patient/clinician input closed January 15, 2021
Clarification:

- Patient input submission received from Arthritis Consumer Experts and Canadian Arthritis Patient Alliance / Arthritis Society/ Cassie and Friends

Submission received December 21, 2020
Submission accepted January 12, 2021
Review initiated January 13, 2021
Clarification:

- Submission temporarily suspended

- Voluntarily withdrawn by the sponsor on 27 Oct 2021